Generic Name and Formulations:
Amoxapine 25mg, 50mg, 100mg, 150mg; tabs.
Indications for Amoxapine:
Depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. Depression accompanied by anxiety or agitation.
Initially 50mg 2–3 times daily; may increase to 100mg 2–3 times daily by the end of the first week. May increase above 300mg/day if dose has been ineffective for a period of at least 2 weeks. Maintenance: when effective dosage established, may give as single dose at bedtime (max 300mg). Elderly: initially 25mg 2–3 times daily; may increase by the end of the first week to 50mg 2–3 times daily. May increase carefully up to 300mg/day if necessary.
Within 14 days of MAOIs. During acute recovery phase following MI.
Monitor for clinical worsening, suicidality, and unusual changes in behavior, esp. during initial few months of treatment and during dose changes. Screen for bipolar disorder prior to initiating therapy. Urinary retention. Angle-closure glaucoma. Increased intraocular pressure. Cardiovascular disorders (monitor closely). Seizure disorders. Discontinue if rash, fever, tardive dyskinesia or neuroleptic malignant syndrome develop. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers.
During or within 5 weeks of fluoxetine. Hyperpyretic crises, severe convulsions, and death with MAOIs (see Contraindications). Potentiates alcohol, barbiturates, other CNS depressants. Paralytic ileus with anticholinergics. Monitor serum levels with CYP450 2D6 inhibitors (eg, quinidine, cimetidine, phenothiazines, propafenone, flecainide, others: see literature). Caution with concomitant electroshock therapy.
Drowsiness, dry mouth, constipation, blurred vision, CNS effects (eg, anxiety, insomnia, restlessness, nervousness, palpitations, tremors, confusion, excitement, nightmares, ataxia, alterations in EEG patterns), edema, rash, elevated prolactin levels, nausea, dizziness, headache, fatigue, weakness, excessive appetite, increased perspiration.
Formerly known under the brand name Asendin.
Tabs 25mg, 50mg, 100mg—100; 150mg—30
Endocrinology Advisor Articles
- GLP-1 Agonists Superior to DPP-4 Inhibitors for Reducing HbA1c, Weight in T2D
- Effect of HbA1c and Perioperative Glucose on Postoperative Mortality
- Semaglutide May Be Useful for Treating Obesity in People Without Diabetes
- Once-Daily Oral Contraceptive for Men Shows Promise
- Effect of Growth Hormone Treatment on BMD in Adults With Prader-Willi Syndrome
- American College of Physicians Releases 4 Guidelines for HbA1c Targets in T2D
- Dyslipidemia Drug Indications
- No Difference in Weight Loss Outcomes With Low-Fat vs Low-Carbohydrate Diet
- Damaging Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture
- Gastric Bypass Surgery Linked to Increased Risk for Nonvertebral Fractures
- Updated Clinical Practice Guidelines on Testosterone Therapy in Men With Hypogonadism
- Type 2 Diabetes Associated With Increased Fracture Risk in Postmenopausal Women
- Use of FSH in Early Diagnosis of Turner Syndrome
- Surgical Treatment Better Than Medical Therapy in Severely Obese Adolescents With T2D
- Metformin May Improve Pregnancy Outcomes in Polycystic Ovary Syndrome